Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza

Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.

More from Archive

More from Pink Sheet